The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...
US aid freeze affects HIV and malaria supply chains, FDA postpones rare disease events, and a leap in Texas measles cases. Meanwhile, Mirum Pharma's drug gets FDA approval, Eli Lilly invests in a ...
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
“We are pleased the FDA has declared that supply of the only real, FDA-approved semaglutide medicines is resolved, affirming ...
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...